Research study to evaluate the efficacy and safety of adjunctive Pimavanserin in subjects with major depressive disorder and inadequate response to antidepressant treatment.

Research study to evaluate the efficacy and safety of adjunctive Pimavanserin in subjects with major depressive disorder and inadequate response to antidepressant treatment.

Brief description of study

We are looking for individuals experiencing treatment-resistant symptoms of depression. This clinical research study is designed to help us understand the efficacy of Pimavanserin as an adjunctive therapy (in addition to another antidepressant) to your current SSRI/SNRI antidepressant. Participants will be randomly assigned either to receive the medication under investigation or a placebo to add to their current antidepressant medication for six weeks. Study participation will last for about 9 weeks (3 weeks screening; 6 weeks treatment) followed by a 30 days follow up period. 

 You may be eligible to participate if currently you are:
 • above 18 years of age 
• Have been treated with one of the SSRI/SNRI antidepressant as per protocol for at least 8 weeks with no relief
 • Have a bMI between 18.5 – 35 kg/m2 

 The clinician will discuss additional study requirements with you if necessary. All medications and treatment will be provided at no cost to you. Compensation for your time and travel may also be provided. On completion of the 6 weeks treatment period, individuals may be eligible to participate in a 52-week open-label extension study.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    depression
  • Age: Between 18 Years - 90 Years
  • Gender: All


Updated on 08 Jul 2023. Study ID: 832801

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center